SCLP — Scancell Holdings Share Price
Last trade - 00:00- £95.28m
- £102.02m
- £5.27m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.07% | ||
| Return on Equity | -320.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Apr | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | 5.27 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. Its lead ImmunoBody cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.
Directors
- John Chiplin NEC
- Lindy Durrant CEO
- Sally Adams OTH (59)
- Robert Miller OTH
- Gillies O'Bryan-Tear OTH
- Martin Diggle NED
- Richard Goodfellow NED
- Susan Clement-Davies NID
- Ursula Ney NID (66)
- Last Annual
- April 30th, 2023
- Last Interim
- October 31st, 2023
- Incorporated
- April 14th, 2008
- Public Since
- July 30th, 2010
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 927,979,977
- Address
- Unit 202 Bellhouse Building, OXFORD, OX4 4GD
- Web
- https://www.scancell.co.uk/
- Phone
- +44 1865582066
- Auditors
- BDO LLP
Latest News for SCLP
Upcoming Events for SCLP
Full Year 2024 Scancell Holdings PLC Earnings Release
Scancell Holdings PLC Annual Shareholders Meeting
Similar to SCLP
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 23:07 UTC, shares in Scancell Holdings are trading at 10.00p. This share price information is delayed by 15 minutes.
Shares in Scancell Holdings last closed at 10.00p and the price had moved by -27.24% over the past 365 days. In terms of relative price strength the Scancell Holdings share price has underperformed the FTSE All Share Index by -34.33% over the past year.
The overall consensus recommendation for Scancell Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Scancell Holdings does not currently pay a dividend.
Scancell Holdings does not currently pay a dividend.
Scancell Holdings does not currently pay a dividend.
To buy shares in Scancell Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 10.00p, shares in Scancell Holdings had a market capitalisation of £92.80m.
Here are the trading details for Scancell Holdings:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: SCLP
Based on an overall assessment of its quality, value and momentum Scancell Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Scancell Holdings is 24.67p. That is 146.7% above the last closing price of 10.00p.
Analysts covering Scancell Holdings currently have a consensus Earnings Per Share (EPS) forecast of -£0.02 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scancell Holdings. Over the past six months, its share price has underperformed the FTSE All Share Index by -14.39%.
As of the last closing price of 10.00p, shares in Scancell Holdings were trading -11.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Scancell Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 10.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Scancell Holdings' management team is headed by:
- John Chiplin - NEC
- Lindy Durrant - CEO
- Sally Adams - OTH
- Robert Miller - OTH
- Gillies O'Bryan-Tear - OTH
- Martin Diggle - NED
- Richard Goodfellow - NED
- Susan Clement-Davies - NID
- Ursula Ney - NID